The prescription market for 'budesonide' asthma drugs has expanded significantly. The drug price hike at the end of last year led to increased production and an expansion of the prescription market. The prescription market has also shown growth due to the resolution of the supply and demand imbalance made for drugs with supply and demand imbalance.

According to the market research institution UBIST, outpatient prescriptions for budesonide single-agent asthma drugs totaled at KRW 6.8 billion in the first half of last year, up 23.0% year-on-year. Prescriptions for budesonide single-agent drugs totaled at KRW 3.1 billion in Q1 this year, up 19.5% YoY, and then at KRW 3.7 billion in Q2, up 26.2% Yoy.